文献速递冠心病血脂与心血管预防

RACING试验:糖尿病合并ASCVD患者中等强度他汀联合依折麦布与高强度他汀比较

Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial.
PubMed 文献 · Eur Heart J · 2023-01-01

RACING试验的糖尿病预设亚组分析纳入1398例(37.0%)糖尿病合并ASCVD患者,比较中等强度他汀联合依折麦布与高强度他汀单药治疗。两组3年主要复合终点发生率分别为10.0%与11.3%(HR 0.89,95%CI 0.64-1.22,P=0.460),联合治疗组不耐受相关停药或减量更少(5.2% vs 8.7%,P=0.014),LDL-C<70 mg/dL达标率更高。

要点

  • 糖尿病合并ASCVD患者中,联合治疗主要终点与高强度他汀单药无显著差异。
  • 联合治疗组不耐受相关停药或减量发生率为5.2%,低于高强度他汀组的8.7%。
  • 联合治疗组1、2、3年LDL-C<70 mg/dL达标率均显著高于单药组。

核心结论

  • RACING试验中观察到的依折麦布联合治疗效应在糖尿病合并ASCVD患者中得以保持。
  • 中等强度他汀联合依折麦布可作为高强度他汀不耐受或需进一步降低LDL-C的糖尿病合并ASCVD患者的合适替代方案。

研究设计与样本

  • RACING试验的预设分层亚组分析,纳入基线糖尿病合并ASCVD患者1398例(占37.0%)。
  • 比较中等强度他汀联合依折麦布与高强度他汀单药治疗,主要终点为3年心血管死亡、主要心血管事件或非致死性卒中的复合终点。

主要发现

  • 糖尿病合并ASCVD患者中,联合治疗组与高强度他汀单药组主要终点发生率分别为10.0%和11.3%(HR 0.89,95%CI 0.64-1.22,P=0.460)。
  • 不耐受相关停药或减量发生率分别为5.2%和8.7%(P=0.014)。
  • 1、2、3年LDL-C<70 mg/dL达标率在联合治疗组分别为81.0%、83.1%、79.9%,单药组分别为64.1%、70.2%、66.8%(均P<0.001)。
  • 总人群中,糖尿病状态与治疗对主要终点、不耐受相关停药或减量、LDL-C<70 mg/dL达标比例均无显著交互作用。

关键数值与推荐

  • 主要终点:3年心血管死亡、主要心血管事件或非致死性卒中的复合终点。
  • LDL-C<70 mg/dL为达标阈值,在1、2、3年评估。

临床怎么用

  • 对于糖尿病合并ASCVD患者,若高强度他汀不耐受或需进一步降低LDL-C,可考虑中等强度他汀联合依折麦布。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This study evaluated the effect of moderate-intensity statin with ezetimibe combination therapy vs. high-intensity statin monotherapy among patients with diabetes mellitus (DM) and atherosclerotic cardiovascular disease (ASCVD). METHODS AND RESULTS: This was a pre-specified, stratified subgroup analysis of the DM cohort in the RACING trial. The primary outcome was a 3-year composite of cardiovascular death, major cardiovascular events, or non-fatal stroke. Among total patients, 1398 (37.0%) had DM at baseline. The incidence of the primary outcome was 10.0% and 11.3% among patients with DM randomized to ezetimibe combination therapy vs. high-intensity statin monotherapy (hazard ratio: 0.89; 95% confidence interval: 0.64-1.22; P = 0.460). Intolerance-related discontinuation or dose reduction of the study drug was observed in 5.2% and 8.7% of patients in each group, respectively (P = 0.014). LDL cholesterol levels <70 mg/dL at 1, 2, and 3 years were observed in 81.0%, 83.1%, and 79.9% of patients in the ezetimibe combination therapy group, and 64.1%, 70.2%, and 66.8% of patients in the high-intensity statin monotherapy group (all P < 0.001). In the total population, no significant interactions were found between DM status and therapy regarding primary outcome, intolerance-related discontinuation or dose reduction, and the proportion of patients with LDL cholesterol levels <70 mg/dL. CONCLUSION: Ezetimibe combination therapy effects observed in the RACING trial population are preserved among patients with DM. This study supports moderate-intensity statin with ezetimibe combination therapy as a suitable alternative to high-intensity statins if the latter cannot be tolerated, or further reduction in LDL cholesterol is required among patients with DM and ASCVD. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, Identifier:NCT03044665.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Lee YJ, Cho JY, You SC, et al. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. Eur Heart J. 2023. PMID: 36529993. doi:10.1093/eurheartj/ehac709

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。